Related Experiment Video

Updated: May 29, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just

J Beyer-Westendorf1, H Büller

  • 1Section Angiology, University Center for Vascular Medicine and Department of Medicine III, University Hospital 'Carl Gustav Carus', Technical University Dresden, Dresden, Germany. jan.beyer@uniklinikum-dresden.de

Journal of Thrombosis and Haemostasis : JTH
|September 17, 2011
PubMed

Insights

This review examines the risks of bias in open-label versus double-blind trials for new oral anticoagulants. It aims to objectively analyze the strengths and weaknesses of each trial design in anticoagulant therapy research.

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Medical Research Methodology

Background:

  • New oral anticoagulants (NOACs) like rivaroxaban, apixaban, edoxaban, and dabigatran are under intense investigation.
  • Phase III trials are evaluating their efficacy and safety for venous thromboembolism and atrial fibrillation stroke prevention.

Purpose of the Study:

  • To address the risks of bias in open-label and double-blind anticoagulation trials.
  • To objectify the debate surrounding the advantages and disadvantages of different trial designs.

Main Methods:

  • Review of existing literature and trial methodologies.
  • Analysis of bias risks for internal and external validity in open-label and double-blind studies.

Main Results:

  • Double-blind trials are generally considered less prone to bias than open-label trials.
  • However, blinded trials are not always feasible, and both designs have complementary strengths and weaknesses.

Conclusions:

  • Understanding the specific risks of bias in each trial design is crucial for interpreting results of new oral anticoagulant studies.
  • A balanced approach is needed to leverage the benefits of both open-label and double-blind methodologies.

Related Concept Videos

Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...